Industry veteran Abbas Hussain named chairman of Asceneuron

18 December 2023

Switzerland-based Asceneuron has announced the appointment of Abbas Hussain as its new chairman of to its board of directors.

Privately-held Asceneuron was created n 2012 as a spin-out of Merck KGaA’s (MRK: DE) Merck Serono division, with the aim of developing therapies for the treatment of Alzheimer's disease and Tau protein-related pathologies, by advancing Merck Serono's pre-clinical programs targeting these conditions towards clinical testing as rapidly as possible.

Mr Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe. He has a strong track record across the pharmaceutical value chain in both mature and emerging markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK